US/UK/Canada

Share

Quotes

Closing the year with a sale to the first customer for our new product is much more than a single sale, it marks the shift from being a pre-revenue company to being a revenue-generating company. For me, this is a long-awaited start to monetizing all the work we have done until now. This is the first very small step in what I expect to be a tremendous growth journey, which takes advantage of the unique position within digital therapeutics for dementia that we have worked to build. I don’t expect it to be easy, but I have no doubt that we have all the right cards on our hand to make this happen
Kim Baden-Kristensen, CEO Brain+ A/S
The collaboration with Brain+ is effective and enjoyable, bringing the best of both worlds to the table. The great unmet clinical need in dementia still stands unanswered and we still see a big need for solutions like the ones we are working on with Brain+. We believe that an ecosystem approach to Alzheimer's and dementia is needed, and we believe digital therapeutics will play an important role
Dr. Nikos Green, Senior Venture Architect & PO Neuroscience, Rox Health
The upcoming launch of our first product is the moment we have been striving for: to be able to offer better therapies to help people living with dementia – and in this case also enable their caregivers to deliver better therapy. Everywhere I go and talk to people in the dementia communities about Brain+ and our digital products, they tell me how important it is for patients what we are doing
Kim Baden-Kristensen, CEO and Co-Founder, Brain+
I am very pleased with the growing interest that we are being met with from big pharma companies in our software solutions and DTx products for dementia. It is key for us to get access to the right resources and competencies to ensure a fast route to commercialization for our products. We are convinced that our DTx solutions offer considerable value for people living with dementia, their relatives, and the healthcare communities around them – and the interest from core pharma players in this field is also an important validation of our business potential
Kim Baden-Kristensen, CEO & Co-founder, Brain+
Pick a time period -
Tags ( Active)

Brain+ A/S – Minutes of Annual General Meeting

Copenhagen, Denmark, 30 May 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Today at 08:00 CEST, the Annual General Meeting was held in Brain+ A/S, (“Brain+” or “the Company”). A total of 16.45 % of shareholder votes and share capital were represented at the meeting, and all the proposals submitted by the Board of Directors were resolved by the meeting with all votes cast and all the share capital represented. All existing members of the Board of Directors were re-elected with Tim Jürgens continuing as Chairman, and Vishal Shah was elected as new board member.Brain+, CVR nr. 36439440,

Leading UK dementia care authority, Antony Hall, joins Brain+ as Strategic Advisor

Copenhagen, Denmark, 28 May 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or “the Company”) has appointed Antony Hall, Managing Director of Park Homes UK, a leading care home group, as Strategic Advisor. The appointment follows the recent agreement between Brain+ and Park Homes UK to deploy Ayla to support high-quality dementia care in the group. Antony Hall is previous Director of HC-One, the largest care provider in the UK, and he has been Lead Inspector for the Care Quality Commission (CQC), which is a respected authority in UK overseeing care quality, dementia

Brain+ signs its second UK sales agreement on Ayla with Park Homes UK Group

Copenhagen, Denmark, 26 May 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or the “Company”), a pioneer in digital dementia care, has signed its second UK customer agreement with Park Homes UK, a leading care home group, operating 21 care homes across England and Scotland. The agreement initially covers deployment of the Ayla platform, a digital Cognitive Stimulation Therapy (CST) assistant, in four (4) of the group’s care homes as part of an implementation and evaluation program. The initial contract value is approximately DKK 68 thousand (£7,600), which covers

Brain+ A/S convenes the Annual General Meeting for 2025

Copenhagen, Denmark, 15 May 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Notice is hereby given to convene the Annual General Meeting for 2025 in Brain+ A/S, CVR. No. 36439440 (“Brain+” or the “Company”) to be held on Friday, 30 May 2025 at 8:00 AM (08:00 CEST). at the Company’s registered address at: Svanevej 22, 2., 2400 København NV, Denmark.The Annual General Meeting will be held with the following agenda. Agenda: 1. Election of chairman of the meeting. 2. The Board of Directors' report on the Company's activities during the past accounting year. 3. Approval of

Brain+ selected for the NHS Dementia Innovators Programme in the UK

Copenhagen, Denmark, 5 May 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or “the Company”) has been selected for the Dementia Innovators Programme in the United Kingdom (UK), a newly launched initiative by the NHS Clinical Entrepreneur Programme in partnership with the Alzheimer’s Society. The programme is application based and supports high-potential innovations addressing critical needs in dementia care, offering participants direct access to NHS commissioners, clinicians and national networks. Brain+’ selection is a validating recognition of the clinical relevance

Brain+ publishes its Annual Report for 2024

Copenhagen, Denmark, April 29, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  In 2024, Brain+ (“Brain+” or the “Company”) realized a net loss of DKK -12.0 million (2023: DKK -19,1 million), which is at the lowest end of the Company’s expectations of a net loss of DKK 12-15 million as presented in the Half-year Report for 2024. For 2025, the Company is forecasted to reach DKK 3.6-3.8 million in cash flow from sales and to continue to expand the reach of its Ayla dementia care platform to build the foundation for operational break-even by mid-2026 as previously announced.Brain+, a

Brain+ appoints CCO Devika Wood as new CEO

Copenhagen, Denmark, 16 April 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or the “Company”) announces that the Board has appointed the Company’s Chief Commercial Officer (CCO), Devika Wood, as new CEO. Devika will take on her new role with immediate effect. Co-founder and former CEO, Kim Baden-Kristensen, will continue as Strategic Advisor to management. The appointment has been agreed by all parties involved and is a natural part of the Company’s ongoing transition from a mainly research and development led organization to a commercially driven healthtech company.

Brain+ announces directed issue of units to convertible loan providers and guarantors

Copenhagen, Denmark, 9 April 2025 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The board of directors in Brain+ A/S (“Brain+” or “the Company”) has today used the authorization from the extraordinary general meeting on 12

Contract signed with Copenhagen Municipality on extended and expanded access to Ayla

Copenhagen, Denmark, 3 April 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+ or “the Company”) and Copenhagen Municipality have agreed to extend their evaluation contract on Ayla – your CST Assistant (“Ayla”) to cover the remaining nine months of the 2025 municipality budget year. At the same time, the contract is expanded from three (3) to up to nine (9) elderly daycare centers getting access to Ayla to scale the delivery of Cognitive Stimulation Therapy (CST). At a discounted one-off evaluation price of DKK 100,000 for the extension, still, the new contract represents

Brain+ announces outcome of unit rights issue

Copenhagen, Denmark, 2 April 2025 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The subscription period in Brain+ A/S’ (“Brain+” or the “Company”) rights issue of units, i.e. the offering of new shares and warrants of series TO

Brain+ A/S informs of last day to subscribe in its ongoing rights issue of units

Copenhagen, Denmark, 26 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Today, Wednesday 26 March 2025, is the last day of trading in the pre-emptive unit rights issued by Brain+ A/S (“Brain+ or ‘the Company”) to its

Brain+ to close first UK Care Home partnership contract with Southcare Homes Group

Copenhagen, Denmark, 25 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or “the Company”) enters a partnership with Southcare Homes Group Ltd (“Southcare Homes”) to introduce Ayla – your CST Assistant (“Ayla”) in initially two (2) of Southcare Homes’ five (5) home and nursing care sites. The partnership covers access to Ayla to support Cognitive Stimulation Therapy (CST) and includes delivery by Brian+ of accredited CST training to selected caregivers. The contract marks a significant milestone in the deployment of Ayla to benefit elderly residents in the UK, and

Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue

Copenhagen, Denmark, 19 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+ or “the Company”) will host a webinar on Friday, 21 March 2025 at 15:00 CET / 14:00 UK time. Link to the webinar . The webinar will feature Vishal Shah, UK care sector expert and new Brain+ advisor and board candidate, who will share his view on the attractive opportunities for the Ayla dementia care platform in the UK care sector. Members of Brain+ management will present the growing

Brain+ expands its UK sales pipeline to €+500,000 in revenue and reveals Key Performance Indicators

Copenhagen, Denmark, 19 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or “the Company”) today reports continued strong momentum in its sales pipeline, now exceeding €500,000 in revenue. Approximately 20% has progressed to advanced stages, with a 90% conversion rate from “Sales-qualified lead” to “Proposal submission”. Expansion in the UK and Denmark continues, with the first UK sales expected imminently and revenue projected to grow exponentially through 2025, aiming to reach €1 million in Annual Recurring Revenues (ARR). Based on a leaner operational model,

The subscription period in Brain+’ rights issue of units begins today

Copenhagen, Denmark, 17 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Today, 17 March 2025, begins the subscription period in Brain+ A/S’ (“Brain+” or the “Company”) issue of units with pre-emptive subscription rights

UK care sector expert, Vishal Shah joins Brain+ as Advisor and Board Observer

Copenhagen, Denmark, 11 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Vishal Shah, a seasoned UK health and care entrepreneur, investor, and non-executive director, joins Brain+ as an Advisor and Board Observer. In this role, Vishal will support the strategic growth and expansion of Ayla, Brain+’ cutting-edge dementia care solution, with a primary focus on the UK care home sector. Vishal brings extensive experience in healthcare investment, digital transformation, and operational healthcare in the care sector, making him a valuable addition to the Board of Directors. He is

The benefits of Ayla – your CST Assistant featured in CareTech, the healthtech media for Danish healthcare professionals

Copenhagen, Denmark, 10 March 2025– Brain+ A/S (Nasdaq First North: BRAINP) A new article in the Danish healthtech media, CareTech, features the benefits of Brain+’ Ayla – your CST Assistant to support group-based Cognitive Stimulation Therapy (CST) to people with dementia. The article is written by professor Rikke Gregersen, VIA University College, who highlights the results from the Danish usability study of Ayla – your CST Assistant, conducted in 2024 in five Danish municipalities and showing extensive user satisfaction with the product. Expert validation is important to build customer

Brain+ resolves to carry out its earlier announced unit rights issue of up to approximately DKK 16 million

Copenhagen, Denmark, 6 March 2025 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board of Directors of Brain+ A/S (“Brain+” or “the Company”) has resolved to carry out the previously announced rights issue of units with

Brain+ A/S – Minutes of Extraordinary General Meeting

Copenhagen, Denmark, 12 February 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Today at 08:00 CEST, an Extraordinary General Meeting was held in Brain+ A/S (“Brain+” or “the Company”). A total of 23.60% of shareholder votes and share capital were represented at the meeting, and all of the proposals submitted by the Board of Directors were resolved by the meeting with all votes cast and all the share capital represented: It was resolved to reduce the share capital of the Company and at the same time reduce the nominal value per share from DKK 0.08 to DKK 0.01 each. The notice to convene

Invitation to Investor Webinar to update on sales outlook, restructuring and secured funding

Copenhagen, Denmark, 30 January 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+ or “the Company”) is inviting its shareholders, other investors and stakeholders to a webinar, which will take place on Monday, 3 Februry 2025 at 15:30 CEST / 14:30 UK time. At the webinar, members of the management team will provide an update on the UK near-term sales outlook and give details on the recently announced operational restructuring of the Company and the intended 50% secured Unit Rights Issue.Brain+ is inviting its shareholders, other investors and stakeholders to a webinar,

Brain+ A/S – Notice of Extraordinary General Meeting

Copenhagen, Denmark, 28 January 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or “the Company”) hereby gives notice for an Extraordinary General Meeting (EGM) of the Company to be held on Wednesday, 12 February 2025 at 08:00 CEST. On the agenda for the EGM will be 1) a proposal to reduce the share capital in the Company and reduce the nominal value per share correspondingly, 2) a proposal to authorize the Board of Directors to resolve on issues of shares and warrants of series TO 5 as part of the announced public unit rights offering intended to be carried out in

Brain+ restructures to reduce OPEX by 35%, maintaining €1M ARR target for end 2025 and now expecting break-even by mid-2026, and announces 50% secured intended Rights Issue

Copenhagen, Denmark, 22 January 2025 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or the “Company”) announces that today, its Board of Directors has decided to carry out a rights issue of units with preferential subscription rights for the Company’s existing shareholders (the “Rights Issue”). The units consist of new Brain+ shares and warrants of series TO 5. The decision to raise new capital is aligned with a comprehensive restructuring initiative to implement a leaner business model, pause new product development and focus all resources on directly revenue-driving

Brain+ announces change of Certified Advisor

Copenhagen, Denmark, 31 December 2024 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or the “Company”) announces that the Company has appointed HC Andersen Capital as its new Certified Advisor. The change will be effective from 1 January 2025. ----Contact Information CEO and Co-founder, Kim Baden-Kristensen: +45 31 39 33 17, kim@brain-plus.com  CFO, Hanne Vissing Leth: +53 88 99 02, hanne@brain-plus.com  - Brain+ Vision Building the world’s first scalable dementia care platform to help people affected by dementia live better lives.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media